|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li D: Molecular epidemiology of pancreatic
cancer. Cancer J. 7:259–265. 2001.PubMed/NCBI
|
|
4
|
Gold EB and Goldin SB: Epidemiology of and
risk factors for pancreatic cancer. Surg Oncol Clin N Am. 7:67–91.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li SH, Fu J, Watkins DN, Srivastava RK and
Shankar S: Sulforaphane regulates self-renewal of pancreatic cancer
stem cells through the modulation of Sonic hedgehog-GLI pathway.
Mol Cell Biochem. 373:217–227. 2013. View Article : Google Scholar
|
|
6
|
Roy SK, Chen Q, Fu J, Shankar S and
Srivastava RK: Resveratrol inhibits growth of orthotopic pancreatic
tumors through activation of FOXO transcription factors. PLoS One.
6:e251662011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shankar S, Ganapathy S, Hingorani SR and
Srivastava RK: EGCG inhibits growth, invasion, angiogenesis and
metastasis of pancreatic cancer. Front Biosci. 13:440–452. 2008.
View Article : Google Scholar
|
|
8
|
Shankar S, Nall D, Tang SN, Meeker D,
Passarini J, Sharma J and Srivastava RK: Resveratrol inhibits
pancreatic cancer stem cell characteristics in human and KrasG12D
transgenic mice by inhibiting pluripotency maintaining factors and
epithelial-mesenchymal transition. PLoS One. 6:e165302011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shankar S, Suthakar G and Srivastava RK:
Epigallocatechin-3-gallate inhibits cell cycle and induces
apoptosis in pancreatic cancer. Front Biosci. 12:5039–5051. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Srivastava RK, Tang SN, Zhu W, Meeker D
and Shankar S: Sulforaphane inhibits self-renewal capacity of
pancreatic cancer stem cells and synergizes with quercetin. Front
Biosci (Elite Ed). 3:515–528. 2011. View
Article : Google Scholar
|
|
11
|
Verma RK, Yu W, Shrivastava A, Shankar S
and Srivastava RK: α-Mangostin-encapsulated PLGA nanoparticles
inhibit pancreatic carcinogenesis by targeting cancer stem cells in
human, and transgenic (Kras(G12D), and Kras(G12D)/tp53R270H) mice.
Sci Rep. 6:327432016. View Article : Google Scholar
|
|
12
|
Zhao M, Tang SN, Marsh JL, Shankar S and
Srivastava RK: Ellagic acid inhibits human pancreatic cancer growth
in Balb c nude mice. Cancer Lett. 337:210–217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shankar S, Singh G and Srivastava RK:
Chemoprevention by resveratrol: Molecular mechanisms and
therapeutic potential. Front Biosci. 12:4839–4854. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shankar S, Siddiqui I and Srivastava RK:
Molecular mechanisms of resveratrol
(3,4,5-trihydroxy-transstilbene) and its interaction with
TNF-related apoptosis inducing ligand (TRAIL) in
androgen-insensitive prostate cancer cells. Mol Cell Biochem.
304:273–285. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jang M and Pezzuto JM: Cancer
chemopreventive activity of resveratrol. Drugs Exp Clin Res.
25:65–77. 1999.PubMed/NCBI
|
|
16
|
Marques FZ, Markus MA and Morris BJ: The
molecular basis of longevity, and clinical implications. Maturitas.
65:87–91. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marzetti E, Wohlgemuth SE, Anton SD,
Bernabei R, Carter CS and Leeuwenburgh C: Cellular mechanisms of
cardioprotection by calorie restriction: state of the science and
future perspectives. Clin Geriatr Med. 25:715–732. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harikumar KB, Kunnumakkara AB, Sethi G,
Diagaradjane P, Anand P, Pandey MK, Gelovani J, Krishnan S, Guha S
and Aggarwal BB: Resveratrol, a multitargeted agent, can enhance
antitumor activity of gemcitabine in vitro and in orthotopic mouse
model of human pancreatic cancer. Int J Cancer. 127:257–268.
2010.
|
|
19
|
Oi N, Jeong CH, Nadas J, Cho YY, Pugliese
A, Bode AM and Dong Z: Resveratrol, a red wine polyphenol,
suppresses pancreatic cancer by inhibiting leukotriene
A4 hydrolase. Cancer Res. 70:9755–9764. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shankar S, Chen Q, Siddiqui I, Sarva K and
Srivastava RK: Sensitization of TRAIL-resistant LNCaP cells by
resveratrol (3,4′,5-tri-hydroxystilbene): Molecular mechanisms and
therapeutic potential. J Mol Signal. 2:72007. View Article : Google Scholar
|
|
21
|
Delmas D, Jannin B and Latruffe N:
Resveratrol: Preventing properties against vascular alterations and
ageing. Mol Nutr Food Res. 49:377–395. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fulda S and Debatin KM:
Resveratrol-mediated sensitisation to TRAIL-induced apoptosis
depends on death receptor and mitochondrial signalling. Eur J
Cancer. 41:786–798. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Patel KR, Scott E, Brown VA, Gescher AJ,
Steward WP and Brown K: Clinical trials of resveratrol. Ann N Y
Acad Sci. 1215:161–169. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Saqui-Salces M and Merchant JL: Hedgehog
signaling and gastrointestinal cancer. Biochim Biophys Acta.
1803:786–795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kinzler KW, Ruppert JM, Bigner SH and
Vogelstein B: The GLI gene is a member of the Kruppel family of
zinc finger proteins. Nature. 332:371–374. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kasper M, Schnidar H, Neill GW, Hanneder
M, Klingler S, Blaas L, Schmid C, Hauser-Kronberger C, Regl G,
Philpott MP, et al: Selective modulation of Hedgehog/GLI target
gene expression by epidermal growth factor signaling in human
keratinocytes. Mol Cell Biol. 26:6283–6298. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ruiz i Altaba A, Sánchez P and Dahmane N:
Gli and hedgehog in cancer: Tumours, embryos and stem cells. Nat
Rev Cancer. 2:361–372. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ramalho-Santos M, Melton DA and McMahon
AP: Hedgehog signals regulate multiple aspects of gastrointestinal
development. Development. 127:2763–2772. 2000.PubMed/NCBI
|
|
29
|
Taylor MD, Liu L, Raffel C, Hui CC,
Mainprize TG, Zhang X, Agatep R, Chiappa S, Gao L, Lowrance A, et
al: Mutations in SUFU predispose to medulloblastoma. Nat Genet.
31:306–310. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tostar U, Malm CJ, Meis-Kindblom JM,
Kindblom LG, Toftgård R and Undén AB: Deregulation of the hedgehog
signalling pathway: A possible role for the PTCH and SUFU genes in
human rhabdomyoma and rhabdomyosarcoma development. J Pathol.
208:17–25. 2006. View Article : Google Scholar
|
|
31
|
Watkins DN, Berman DM, Burkholder SG, Wang
B, Beachy PA and Baylin SB: Hedgehog signalling within airway
epithelial progenitors and in small-cell lung cancer. Nature.
422:313–317. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Berman DM, Karhadkar SS, Maitra A, Montes
De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman
JR, Watkins DN, et al: Widespread requirement for Hedgehog ligand
stimulation in growth of digestive tract tumours. Nature.
425:846–851. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rodova M, Fu J, Watkins DN, Srivastava RK
and Shankar S: Sonic hedgehog signaling inhibition provides
opportunities for targeted therapy by sulforaphane in regulating
pancreatic cancer stem cell self-renewal. PLoS One. 7:e460832012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Singh BN, Fu J, Srivastava RK and Shankar
S: Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits
pancreatic cancer stem cell characteristics: Molecular mechanisms.
PLoS One. 6:e273062011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Magistri P, Battistelli C, Strippoli R,
Petrucciani N, Pellinen T, Rossi L, Mangogna L, Aurello P, D’Angelo
F, Tripodi M, et al: SMO inhibition modulates cellular plasticity
and invasiveness in colorectal cancer. Front Pharmacol. 8:9562018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li X, Wang X, Xie C, Zhu J, Meng Y, Chen
Y, Li Y, Jiang Y, Yang X, Wang S, et al: Sonic hedgehog and
Wnt/β-catenin pathways mediate curcumin inhibition of breast cancer
stem cells. Anticancer Drugs. 29:208–215. 2018.PubMed/NCBI
|
|
37
|
Morgan H, Olivero C and Patel GK:
Identification of human cutaneous basal cell carcinoma cancer stem
cells. Methods Mol Biol. Apr 20–2018.(Epub ahead of print).
View Article : Google Scholar
|
|
38
|
Tong W, Qiu L, Qi M, Liu J, Hu K, Lin W,
Huang Y and Fu J: GANT-61 and GDC-0449 induce apoptosis of prostate
cancer stem cells through a GLI-dependent mechanism. J Cell
Biochem. 119:3641–3652. 2018. View Article : Google Scholar
|
|
39
|
Wang K, Pan L, Che X, Cui D and Li C: Gli1
inhibition induces cell-cycle arrest and enhanced apoptosis in
brain glioma cell lines. J Neurooncol. 98:319–327. 2010. View Article : Google Scholar
|
|
40
|
Tsuda N, Ishiyama S, Li Y, Ioannides CG,
Abbruzzese JL and Chang DZ: Synthetic microRNA designed to target
glioma-associated antigen 1 transcription factor inhibits division
and induces late apoptosis in pancreatic tumor cells. Clin Cancer
Res. 12:6557–6564. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cho WC: MicroRNAs in cancer - from
research to therapy. Biochim Biophys Acta. 1805:209–217. 2010.
|
|
43
|
Guo S, Fesler A, Wang H and Ju J: microRNA
based prognostic biomarkers in pancreatic Cancer. Biomark Res.
6:182018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar
|
|
45
|
Nicoloso MS, Spizzo R, Shimizu M, Rossi S
and Calin GA: MicroRNAs - the micro steering wheel of tumour
metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fu J, Rodova M, Roy SK, Sharma J, Singh
KP, Srivastava RK and Shankar S: GANT-61 inhibits pancreatic cancer
stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice
xenograft. Cancer Lett. 330:22–32. 2013. View Article : Google Scholar
|
|
47
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
48
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Iwatsuki M, Mimori K, Yokobori T, Ishi H,
Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal
transition in cancer development and its clinical significance.
Cancer Sci. 101:293–299. 2010. View Article : Google Scholar
|
|
50
|
Wellner U, Schubert J, Burk UC,
Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D,
zur Hausen A, et al: The EMT-activator ZEB1 promotes tumorigenicity
by repressing stemness-inhibiting microRNAs. Nat Cell Biol.
11:1487–1495. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hsieh TC, Wong C, John Bennett D and Wu
JM: Regulation of p53 and cell proliferation by resveratrol and its
derivatives in breast cancer cells: An in silico and biochemical
approach targeting integrin αvβ3. Int J Cancer. 129:2732–2743.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hsieh TC, Huang YC and Wu JM: Control of
prostate cell growth, DNA damage and repair and gene expression by
resveratrol analogues, in vitro. Carcinogenesis. 32:93–101. 2011.
View Article : Google Scholar
|
|
53
|
Fritz S, Fernández-del Castillo C, Iafrate
AJ, Mino-Kenudson M, Neyhard N, LaFemina J, Stirman A, Warshaw AL
and Thayer SP: Novel xenograft and cell line derived from an
invasive intraductal papillary mucinous neoplasm of the pancreas
give new insights into molecular mechanisms. Pancreas. 39:308–314.
2010. View Article : Google Scholar
|
|
54
|
Nissim S, Idos GE and Wu B: Genetic
markers of malignant transformation in intraductal papillary
mucinous neoplasm of the pancreas: A meta-analysis. Pancreas.
41:1195–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nolan-Stevaux O, Lau J, Truitt ML, Chu GC,
Hebrok M, Fernández-Zapico ME and Hanahan D: GLI1 is regulated
through Smoothened-independent mechanisms in neoplastic pancreatic
ducts and mediates PDAC cell survival and transformation. Genes
Dev. 23:24–36. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lauth M and Toftgård R: Hedgehog signaling
and pancreatic tumor development. Adv Cancer Res. 110:1–17. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Thayer SP, di Magliano MP, Heiser PW,
Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernándezdel
Castillo C, Yajnik V, et al: Hedgehog is an early and late mediator
of pancreatic cancer tumorigenesis. Nature. 425:851–856. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tang SN, Fu J, Nall D, Rodova M, Shankar S
and Srivastava RK: Inhibition of sonic hedgehog pathway and
pluripotency maintaining factors regulate human pancreatic cancer
stem cell characteristics. Int J Cancer. 131:30–40. 2012.
View Article : Google Scholar :
|
|
59
|
Tang SN, Singh C, Nall D, Meeker D,
Shankar S and Srivastava RK: The dietary bioflavonoid quercetin
synergizes with epigallocathechin gallate (EGCG) to inhibit
prostate cancer stem cell characteristics, invasion, migration and
epithelial-mesenchymal transition. J Mol Signal. 5:142010.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kurahara H, Takao S, Maemura K, Mataki Y,
Kuwahata T, Maeda K, Ding Q, Sakoda M, Iino S, Ishigami S, et al:
Epithelial-mesenchymal transition and mesenchymal-epithelial
transition via regulation of ZEB-1 and ZEB-2 expression in
pancreatic cancer. J Surg Oncol. 105:655–661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Pantel K, Alix-Panabières C and Riethdorf
S: Cancer microme-tastases. Nat Rev Clin Oncol. 6:339–351. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Baffa R, Fassan M, Volinia S, O’Hara B,
Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM, et
al: MicroRNA expression profiling of human metastatic cancers
identifies cancer gene targets. J Pathol. 219:214–221. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Baranwal S and Alahari SK: miRNA control
of tumor cell invasion and metastasis. Int J Cancer. 126:1283–1290.
2010.
|
|
64
|
Nalls D, Tang SN, Rodova M, Srivastava RK
and Shankar S: Targeting epigenetic regulation of miR-34a for
treatment of pancreatic cancer by inhibition of pancreatic cancer
stem cells. PLoS One. 6:e240992011. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
O’Brien SJ, Carter JV, Burton JF, Oxford
BG, Schmidt MN, Hallion JC and Galandiuk S: The role of the miR-200
family in epithelial-mesenchymal transition in colorectal cancer: A
systematic review. Int J Cancer. 142:2501–2511. 2018. View Article : Google Scholar
|
